Rivermark Medical's FloStent System for Symptomatic BPH Evaluated in RAPID-1 FIH Study
January 10, 2023—Rivermark Medical, a developer of a first-line device therapy for benign prostatic hyperplasia (BPH), announced the successful
Source: evtoday.com